US$ 21.85
glp-1 inventor Reflections on the discovery as a satiety hormone: Implications for obesity therapy and future directions Leading GLP-1 expert shares insights
Description
La aprobacin otorgada a Novo Nordisk ampla el uso indicado del agonista de GLP-1 para incluir dosis de 0,5, 1,0 y 2,0 mg para el tratamiento de la DMT2, as como indicaciones para reducir el riesgo de eventos cardiovasculares adversos mayores en adultos con DMT2 y enfermedad cardiovascular

(2023, January 12)

M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study)

Snack: 1 oz macadamia nuts (20g fat, 2g carbs)energy without sugar spikes

A revolution in obesity treatment

Gen Z (79%) agreed with this the most compared to millennials (75%) and Gen X (58%)
